Reduced Intensity Hematopoietic Cell Transplantation for Patients With Resistant Langerhans Cell Histiocytosis
Status:
Terminated
Trial end date:
2013-05-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Giving a monoclonal antibody, such as alemtuzumab, and chemotherapy drugs, such as
fludarabine and melphalan, before a donor stem cell transplant helps stop the patient's
immune system from rejecting the donor's stem cells and helps stop the growth of abnormal
cells. When the healthy stem cells from a donor are infused into the patient they may help
the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets.
Sometimes the transplanted cells from a donor can make an immune response against the body's
normal cells. Giving cyclosporine and mycophenolate mofetil before and after transplant may
stop this from happening.
PURPOSE: This phase II trial is studying how well giving alemtuzumab together with
fludarabine and melphalan followed by a donor stem cell transplant works in treating young
patients with resistant Langerhans cell histiocytosis.